The Latest Breaking News on Heart Disease

Bristol Myers Squibb Co. (NYSE:BMY), in collaboration with Johnson Johnson (NYSE:JNJ), announced Friday that they decided to stop the Phase 3 Librexia ACS trial evaluating the efficacy and safety of milvexian when added to the standard of care (conventional antiplatelet therapy) for patients after a recent acute coronary syndrome (ACS)…

The number of Australians dying from a prevalent disease has hit an almost 50-year low while mortality rates for dementia have been steadily rising.

The FDA has removed black box warnings from menopause hormone therapy drugs, marking a major milestone for women's health after decades of fear over outdated risks.

Researchers call for rigorous monitoring protocol to adjust vitamin D supplementation every three months

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on Sunday shared results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG), a condition characterized by dangerously high triglyceride (fat) levels.

The Food and Drug Administration says it will remove a long-standing warning from hormone-based drugs used to treat menopause symptoms in women

Trial’s findings go against common beliefs that people with atrial fibrillation should avoid caffeinated coffee

NHS officials said there are not enough donations to meet demand.

The single dose treatment helped patients lower “bad” cholesterol and triglyerides, both linked to heart disease